Ingevity Corporation Announces Exclusive Distribution Partnership with Jamplast for Capa® Caprolactone in U.S. and Canada

Reuters
06 Jun
Ingevity Corporation Announces Exclusive Distribution Partnership with Jamplast for Capa® Caprolactone in U.S. and Canada

Ingevity Corporation has announced a new partnership with Jamplast, appointing them as the exclusive distributor for Ingevity's Capa® caprolactone products in the United States and Canada. This collaboration aims to enhance the distribution network for bioplastics, leveraging Jamplast's expertise in the distribution of biopolymers and thermoplastics. The partnership, effective from April 23, 2025, aligns with both companies' commitment to advancing sustainable solutions within the bioplastics industry. Ingevity's innovative products coupled with Jamplast's extensive market reach is expected to drive significant impact in the transition to a more sustainable future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ingevity Corporation published the original content used to generate this news brief on June 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10